ACTG — Acacia Research Corporation

Acacia Research Corporation (ACTG) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenue: $114.6 million, up from $51.2 million in Q2 2025.
• Adjusted EBITDA: $17.3 million; Operating segment adjusted EBITDA was $22.8 million.
• Net Income: GAAP net income of $47,000 ($0.00 per diluted share); Adjusted net income of $12.8 million ($0.13 per diluted share).
• Cash Position: $334.6 million in cash, securities, and loans receivable; no parent company debt.
• Segment Performance:
  • Benchmark: Revenue of $20.5 million, adjusted EBITDA of $9.8 million.
  • Deflecto: Revenue of $27.1 million, adjusted EBITDA of $1.1 million.
  • Printronix: Revenue of $6 million, adjusted EBITDA of $1 million.
  • Intellectual Property: Licensing revenue of approximately $60.6 million, adjusted EBITDA of $10.9 million.

2. Strategic Updates and Business Highlights:

• Continued focus on disciplined capital allocation and long-term intrinsic value creation.
• Strong performance from Benchmark, with ongoing development of drilling opportunities.
• Deflecto is undergoing manufacturing optimization and restructuring for future growth.
• Printronix is leveraging its installed base for higher-margin products.
• The Intellectual Property segment saw significant licensing activity, particularly in the Wi-Fi 6 portfolio, despite the episodic nature of licensing revenue.
• Active evaluation of acquisition opportunities across various industries, with a strong pipeline noted.

3. Forward Guidance and Outlook:

• Acacia remains optimistic about future licensing opportunities within its Intellectual Property portfolio.
• The company is positioned to capitalize on attractive acquisition opportunities due to its strong balance sheet and disciplined investment approach.
• Continued focus on maximizing long-term value rather than short-term earnings.

4. Bad News, Challenges, or Points of Concern:

• Deflecto's performance has not yet reflected positive industry trends, indicating potential operational challenges.
• A full write-down of the investment in Viamet Pharmaceuticals due to liquidity issues faced by Mycovia Pharmaceuticals, which could impact the Life Sciences portfolio.
• Legal expenses related to legacy litigation matters have been a burden, with $3.7 million incurred in Q2, which is not expected to recur.
• The competitive landscape remains challenging, particularly in the Intellectual Property space, where settlements can be unpredictable.

5. Notable Q&A Insights:

• Benchmark's free cash flow and EBITDA include contributions from newly operational wells, with plans to drill additional wells based on favorable performance metrics.
• Deflecto is expected to benefit from improving demand, although current results do not reflect this yet.
• The company sees increased deal flow opportunities due to current market conditions, particularly with private equity and credit situations.
• Clarification on the Intellectual Property segment indicated that the reported EBITDA does not fully reflect net cash received from licensing settlements due to high contingency fees and legal costs associated with settlements.

Overall, Acacia Research Corporation reported a strong quarter with significant revenue growth and strategic initiatives in place, while also navigating challenges in certain segments and maintaining a cautious outlook on future performance.